Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine, Houston, Texas, USA.
Texas Children's Hospital, Houston, TX, USA.
J Oncol Pharm Pract. 2021 Mar;27(2):376-388. doi: 10.1177/1078155220979047. Epub 2020 Dec 18.
Blinatumomab is the first in its class bispecific T-cell engager monoclonal antibody, which binds to CD19 expressed on B-cells and CD3 expressed on T-cells, resulting in lysis of CD19-positive cells common in B-cell malignancies. Blinatumomab is Food and Drug Administration (FDA) approved for the treatment of adults and children with relapsed/refractory or minimal residual disease (MRD) positive precursor B-cell ALL (B-ALL). Despite impressive efficacy for the approved indications and favorable toxicity profile compared to standard-of-care chemotherapy, blinatumomab presents unique health-system challenges related to preparation, administration, toxicity monitoring and medication error prevention. Blinatumomab delivery also offers plethora of opportunities for interdisciplinary planning and collaboration. The purpose of this paper is to discuss practical considerations for safe blinatumomab delivery from the pharmacy and nursing perspectives.
Blinatumomab 是首个双特异性 T 细胞衔接单克隆抗体类药物，与表达在 B 细胞上的 CD19 和 T 细胞上的 CD3 结合，导致 B 细胞恶性肿瘤中常见的 CD19 阳性细胞裂解。Blinatumomab 获美国食品和药物管理局 (FDA) 批准，用于治疗成人和儿童复发/难治性或微小残留病灶 (MRD) 阳性前体 B 细胞急性淋巴细胞白血病 (B-ALL)。尽管在批准的适应证中疗效显著，与标准护理化疗相比毒性谱较好，但与 blinatumomab 相关的独特的卫生系统挑战与准备、管理、毒性监测和药物错误预防有关。Blinatumomab 的输送也为跨学科规划和协作提供了丰富的机会。本文的目的是从药学和护理的角度讨论安全输送 blinatumomab 的实际注意事项。
